Phân tích dược động học quần thể về các tương tác thuốc giữa risperidone, bupropion và sertraline trên chuột CF1

Addington D, Addington J, Patten S, Remington G, Moamai J, Labelle A, Beauclair L (2002) Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol 22:20–25 Aguilar MA, Rodriguez-Arias M, Mari-Sanmillan MI, Minarro J (1997) Effects of risperidone on conditioned avoidance responding in male mice. Behav Pharmacol 8:669–876 Alfaro CL, Lam YW, Simpson J, Ereshefsky L (2000) CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 40:58–66 Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131–1152 Boulton DW, DeVane CL, Liston HL, and Markowitz JS (2002) Human recombinant P-glycoprotein specificity for atypical antipsychotics. Life Sci 71:163–169 Bourin M, Colombel MC, Redrobe JP, Nizard J, Hascoet M, Baker GB (1998) Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages. Prog Neuropsychopharmacol Biol Psychiatry 22:343–351 Cooper TB, Suckow RF, Glassman A (1984) Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. J Pharm Sci 73:1104–1107 Coryell W (1996) Psychotic depression. J Clin Psychiatry 57 (Suppl 3):27–31 Cox DS, Scott KR, Gao H, Eddington ND (2002) Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. J Pharmacol Exp Ther 302:1096–1104 DeVane CL (1998) Translational pharmacokinetics: current issues with newer antidepressants. Depress Anxiety 8 (Suppl 1):64–70 DeVane CL, Liston HL, Markowitz JS (2002) Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 41:1247–1266 Dodd S, Stocky A, Buist A, Burrows GD, Maguire K, Norman TR (2000) Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Hum Psychopharmacol 15:161–264 Eap CB, Bondolfi G, Zullino D, Bryois C, Fuciec M, Savary L, Jonzier-Perey M, Baumann P (2001) Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Ther Drug Monit 23:228–231 Fang J, Bourin M, Baker GB (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359:147–151 Guzey C, Norstrom A, Spigset O (2002) Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit 24:436–437 He H, Richardson JS (1995) A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol 10:19–30 Hermann RC, Yang D, Ettner SL et al (2002) Prescription of antipsychotic drugs by office-based physicians in the United Sates, 1989–1997. Psychiatr Serv 53:425–430 Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176–1183 Karow A, Lambert M (2003) Polypharmacy in treatment with psychotropic drugs: the underestimated phenomenon. Curr Opin Psychiatry 16:713–718 Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K (1999) Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 27:763–766 Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, Adson DE (2005) Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 25:226–229 Kurt M, Arik AC, Celik S (2000) The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice. J Basic Clin Physiol Pharmacol 11:173–180 Laizure SC, DeVane CL (1985) Stability of bupropion and its major metabolites in human plasma. Ther Drug Monit 7:447–450 Lane RM (1996) Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 11 (Suppl 5):31–61 Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J (2002) Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 22:169–173 Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW (2002). Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029–1037 Mauri MC, Laini V, Cerveri G, Scalvini ME, Volonteri LS, Regispani F, Malvini L, Manfre S, Boscati L, Panza G (2002) Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 26:597–601 Obach RS, Cox LM, Tremaine LM (2005) Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 33:262–270 Pirraglia PA, Stafford RS, Singer DE (2003) Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiat 5:153–157 Pollock BG, Sweet RA, Kirshner M, Reynolds CF 3rd (1996) Bupropion plasma levels and CYP2D6 phenotype. Ther Drug Monit 18:581–585 Ronfeld RA, Tremaine LM, Wilner KD (1997) Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 32 (Suppl 1):22–30 Shad MU, Preskorn SH (1997) A possible bupropion and imipramine interaction. J Clin Psychopharmacol 17:118–119 Shin JG, Soukhova N, Flockhart DA (1999) Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 27:1078–1084 Spina E, Scordo MG, D'Arrigo C (2003) Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17:517–538 Spina E, D'Arrigo C, Migliardi G, Morgante L, Zoccali R, Ancione M, Madia A (2004) Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit 26:386–390 Tohen M, Vieta E, Calabrese J et al (2003) Efficacy of olanzapine and olanzapine–bluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079–1088 Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL (2004a) The brain entry of risperidone and 9-hydroxyrisperidone are greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 7:415–419 Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, DeVane CL (2004b) Olanzapine penetration into brain is greater in transgenic Abcb 1a P-glycoprotein deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 29:551–557 Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE (2003) Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305:197–204